Amphotericin B Toxicity

Clinical Staff Conference1 August 1964Amphotericin B ToxicityCombined Clinical Staff Conference at the National Institutes of HealthJOHN P. UTZ, M.D., JOHN E. BENNETT, M.D., MICHAEL W. BRANDRISS, M.D., WILLIAM T. BUTLER, M.D., GEORGE J. HILL II, M.D.JOHN P. UTZ, M.D.Search for more papers by this author, JOHN E. BENNETT, M.D.Search for more papers by this author, MICHAEL W. BRANDRISS, M.D.Search for more papers by this author, WILLIAM T. BUTLER, M.D.Search for more papers by this author, GEORGE J. HILL II, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-61-2-334 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIntroductionJOHN P. UTZ, M.D.,Bethesda, MarylandSince 1957 amphotericin B has been employed in the treatment of systemic fungal disease patients being studied at the Clinical Center. Diseases in which the drug has been useful include blastomycosis, histoplasmosis, cryptococcosis, coccidioidomycosis, aspergillosis, sporotrichosis, and candidiasis. The magnitude of effectiveness of the drug is best illustrated by its record in cryptococcal meningitis. Before 1957 and the introduction of amphotericin B, this disease had been universally fatal. At the very least there had not been a report of survival of a single patient. Treatment with amphotericin B has reduced the case fatality... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Bethesda, MarylandThis is an edited transcription of a combined clinical staff conference at the Clinical Center, Bethesda, Maryland, by the Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Public Health Service, Department of Health, Education, and Welfare.Requests for reprints should be addressed to John P. Utz, M.D., Chief, Infectious Disease Service, Bethesda, Maryland 20014. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPancreas preservation with amphotericin B deteriorates islet yield for porcine islet isolationA rare case of Cryptococcus luteolus-related tenosynovitisAntifungal prophylaxis during treatment for haematological malignancies: are we there yet?Cryptococcosis: From Discovering the Natural Reservoir of its Etiology to the Genetic Manipulation of Cryptococcus neoformans: Milestones in Cryptococcal Research by Intramural Investigators at NIAIDTargeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasisTriad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological CharacteristicsPancreatic toxicity after liposomal amphotericin B . Pankreastoxizitat nach liposomalem Amphotericin BLiposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and childrenAgents for treatment of invasive fungal infectionsLipid-based formulations of amphotericin BTargeting of Liposomal Andrographolide to L.donovani -Infected Macrophages in VivoToxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate—fat emulsion in HIV-infected patients with oral candidosisAmphotéricine B déoxycholate (Fungizone®): vieux médicament, nouvelles versionsFluconazole vs. Amphotericin B for the Treatment of Neonatal Fungal Septicemia: A Prospective Randomized TrialVitrectomy and Systemic Fluconazole for Treatment of Endogenous Fungal EndophthalmitisAmphotéricine B désoxycholate (Fungizone®): vieux médicament, nouvelles versionsAmphotericin B Infusion-Related Toxicity: Comparison of Two- and Four-Hour InfusionsAmphotericin B Toxicity Reduced by Administration in Fat EmulsionRapid Infusion of Amphotericin B in DextroseTwo-hour versus six-hour administration of amphotericin B in the treatment of kala-azarHistoplasma Capsulatum Infection in Three AIDS Patients Living in AfricaUse of Antifungal Therapy in Hospitalized Patients I. Results Prior to the Marketing of FluconazoleAre incremental doses of amphotericin B required for the treatment of visceral leishmaniasis?Liposomal amphotericin B (AmBisome®) treatment of invasive fungal infections in immunocompromised childrenManagement of Infection in Patients with Acute LeukemiaRisk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients with preserved renal functionTrial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.Rapid infusion of amphotericin B: Is it safe, effective, and wise?Early Pharmacokinetic and Clinical Results from a Noncomparative Multicentre Trial of Amphotericin B Encapsulated in a Small Unilamellar Liposome (AmBisome®)Direct amphotericin B-mediated tubular toxicity: Assessments of selected cytoprotective agentsInfluence of Infusion Time on the Acute Toxicity of Amphotericin B: Results of a Randomized Double-Blind StudyAmphotericin BRandomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durationsDrug Information Analysis ServiceAntifungal drugs-an introductionFungal Infections in Cancer PatientsEffect of Infusion Rate on Amphotericin B-Associated Febrile ReactionsTopical and Systemic Antifungal AgentsChronic Amphotericin B Nephrotoxicity in the Rat, Protective Effect of Prophylactic Salt LoadingFungal Infections in the Compromised HostAntifungal Agents Used for Deep-Seated Mycotic InfectionsManagement of Infections in Children with CancerAmphotericin B — A Model Murine ImmunostimulantBenefit-risk Assessment of Investigational Drugs: Current Methodology, Limitations, and Alternative ApproachesAmphotericin—How Safe and Effective?Effect of Filtering Amphotericin B Infusions on the Incidence and Severity of Phlebitis and Selected Adverse ReactionsAmphotericin B fever in rabbitsAntifungal, Anthelmintic, and Antiprotozoal DrugsChemotherapy of the Systemic MycosesFungal Pneumonias: Pulmonary Coccidioidal Syndromes (Part 2)Treatment of fungal infections of the central nervous systemStimulation of human and canine neutrophil metabolism by amphotericin BWhether or not to Administer Amphotericin to an Immunosuppressed Patient with Hematologic Malignancy and Undiagnosed FevertINFECTIOUS COMPLICATIONS IN THE CANCER PATIENTAn evolution of therapy for mucocutaneous candidiasisIn vitro activities of miconazole, miconazole nitrate, and ketoconazole alone and combined with rifampin against Candida spp. and Torulopsis glabrata recovered from cancer patientsA Review of Complications of Amphotericin-B Therapy: Recommendations for Prevention and ManagementCoccidioidal MeningitisDiagnosis and Treatment of Systemic MycosesErythropoietin Concentration in Amphotericin B-Induced AnemiaHearing Loss as a Sequela of MeningitisAntifungal agentsKomplikationen und supportive Therapie der Leukämien und malignen Non-Hodgkin-LymphomeOcular and orbital phycomycosisBone Marrow Toxicity Associated with 5-Fluorocytosine TherapyAmphotericin inhibition of hematopoiesis in vitroSimple Assay for 5-Fluorocytosine in the Presence of Amphotericin BImmunologic monitoring and aspergillosis in renal transplant patientsAllergic Rash Due to Amphotericin BBENNETT LORBER, M.D., CHARLES CUTLER, M.D., WILLIAM E. BARRY, M.D.Successful control of systemic aspergillus niger infections in two patients with acute leukemiaActions and Uses of Antimicrobial Agents in the Treatment of Musculoskeletal InfectionsLaboratory tests of antifungal drugs.Antimicrobial Agents in the Treatment of Obstetric and Gynecologic InfectionsAlteration of Tyrosine Aminotransferase Activity in Hepatoma Cells in Tissue Culture by Amphotericin BChemotherapy of Systemic MycosesEsophageal MycosesStability of Amphotericin B in Infusion BottlesTreatment of infective endocarditis—1973Toxicity of Intravitreal Injection of Amphotericin BEffect of Amphotericin B on Sodium and Water Movement Across Normal and Cholera Toxin-Challenged Canine JejunumManagement of acute leukemiaAmphotericin B Methyl Ester Hydrochloride and Amphotericin B: Comparative Acute ToxicityA Subcutaneous Reservoir for Intrathecal Therapy of Fungal MeningitisClotrimazole (Bay b 5097): In Vitro and Clinical Pharmacological StudiesAspergillosis in Four Renal Transplant Recipients Diagnosis and Effective Treatment with Amphotericin BJOHN R. BURTON, M.D., J. B. ZACHERY, M.D., R. BESSIN, M.D., H. K. RATHBUN, M.D., W. B. GREENOUGH III, M.D., S. STERIOFF, M.D., J. R. WRIGHT, M.D., R. E. SLAVIN, M.D., G. M. WILLIAMS, M.D.Hypocalcemia—a complication of childhood leukemiaCryptococcosisCryptococcosisTreatment of candida septicaemia in a severely scalded child with amphotericin B.Fever in aspergillus mycetomaSuccessful Treatment of Chronic Esophageal Moniliasis with a Viscous Suspension of NystatinClearance of amphotericin B-C14 from cerebrospinal fluidCoccidioidal Pulmonary CavitationRenal Tubular Acidosis Due to Amphotericin BUnusual Antimicrobial Toxic ReactionsRecognition and Current Management of the Systemic MycosesPulmonary Cryptococcosis Must All Receive Amphotericin B?VERNON N. HOUK, KENNETH M. MOSER, M.D., F.A.C.P. 1 August 1964Volume 61, Issue 2Page: 334-334KeywordsAmphotericinDrugsFungal diseasesHistoplasmosisInfectious diseasesMedical servicesPrevention, policy, and public healthResearch laboratoriesSporotrichosisToxicity Issue Published: 1 August 1964 PDF DownloadLoading ...